Lakewood-Amedex Reports Wider Q1 Losses, ($0.20) EPS and Negative Revenue
LABT is trading near its 52-week low of $0.69 (2.7% above the low) on light trading volume (0.1× avg).
Summary
Lakewood-Amedex Biotherapeutics reported wider Q1 2026 losses, with revenue at ($886.75K), a net loss of ($923.29K), and diluted EPS of ($0.2). All key financial metrics worsened year-over-year. This earnings summary follows the company's recent 10-Q filing, which disclosed a persistent going concern warning and significant net losses. For a micro-cap company already trading near its 52-week low, these worsening financial results highlight continued cash burn and a precarious financial position, despite a recent $6.8 million Series C financing.
At the time of this announcement, LABT was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.9M. The 52-week trading range was $0.69 to $9.82. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.